Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + endostatin + chemotherapy
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy regimen is a neoadjuvant treatment protocol being investigated for patients with unresectable stage III non-small cell lung cancer (NSCLC). It integrates three therapeutic pillars: immunotherapy with **tislelizumab** (a humanized IgG4 anti-PD-1 monoclonal antibody), anti-angiogenic therapy with **recombinant human endostatin** (marketed as Endostar), and cytotoxic **chemotherapy** (typically carboplatin combined with either pemetrexed for non-squamous histology or nab-paclitaxel for squamous histology). Tislelizumab functions by blocking the PD-1/PD-L1 pathway to restore T-cell mediated anti-tumor immunity, while endostatin inhibits tumor vascularization by interfering with pro-angiogenic signaling. The regimen is being evaluated in a prospective, multicenter Phase II trial led by investigator Hua Zhang to determine its efficacy in achieving surgical conversion and improving clinical outcomes in locally advanced NSCLC.
- Other names
- tislelizumab + endostatin-Hua Zhang-non-small cell lung cancerTislelizumab + Endostar + ChemotherapyTislelizumab Combined With Recombinant Human Endostatin Injection Plus Chemotherapy
02
Targets
TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tislelizumab + endostatin + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + endostatin + chemotherapy.